The number of methicillin resistant Staphylococcus aureus or MRSA infections has been increasing and become a serious problem in public heath worldwide. The use of bacteriocin as an alternative agent to overcome this problem is promising. The partially purified bacteriocin or PPB obtained from strain WARY9-1M showed broad antimicrobial activity.The most sensitive strains were MRSA and S. aureus. The PPB was heat stable up to 100°C for 60 min and active within the pH range of 3-9. The complete inactivation after treatment with all proteolytic enzymes (trypsin, a-chymotrypsin and proteinase K) reveals its proteinaceous nature. This isolated strain can be regarded as bacteriocin producing bacteria or BAC. It was identified as Bacillus amyloliquefaciens by 16S rRNA gene sequence. Tris-Tricine SDS-PAGE analysis revealed that bacteriocin from strain WARY9-1M had an apparent molecular weight of 3 kDa. PCR analysis showed the presence of malonyl CoA transacylase (ituD) and lichenysin synthetase C (lchAC). The novel bioactive peptide from B. amyloliquefaciens strain WARY9-1M has a potential for use as an alternative antibacterial agent for the treatment of infection with MRSA in the future.